Skip to main content
  • Prescribing Information
  • Important Safety Information
  • For US Patients
  • Register for Updates
  • Find a Rep
RYBREVANT® Logo
  • Find a Rep
Register for Updates
  • EGFR Exon 20 Insertion Mutations
  • Mechanism of Action
  • Efficacy
  • Safety
  • Dosing and Administration
  • Support and Resources
  • Prescribing Information
  • Important Safety Information
  • For US Patients
  • Register for Updates
  • Find a Rep

Site Map

  • EGFR Exon 20 Insertion Mutations
    • Biomarker Testing
    • Mechanism of Disease
  • Mechanism of Action
    • Mechanism of Action
    • MOA Video
  • Efficacy
    • CHRYSALIS Study Design
    • Results From CHRYSALIS
  • Safety
    • Warnings and Precautions
    • Safety Profile
  • Dosing and Administration
    • Premedication and Dosing
    • Dose Modification
    • Administration
  • Support and Resources
    • HCP Resources
    • Patient Resources
    • Access Support
    • Patient Support
  • Privacy Policy
  • Contact Us
  • Legal Notice
INDICATION

RYBREVANT® (amivantamab-vmjw) is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Infusion-Related Reactions

RYBREVANT® can cause infusion-related reactions (IRR); signs and symptoms of IRR include dyspnea, flushing, fever, chills, nausea, chest discomfort, hypotension, and vomiting.

Based on the safety population, IRR occurred in 66% of patients treated with RYBREVANT®. Among patients receiving treatment on Week 1 Day 1, 65% experienced an IRR, while the incidence of IRR was 3.4% with the Day 2 infusion, 0.4% with the Week 2 infusion, and cumulatively 1.1% with subsequent infusions. Of the reported IRRs, 97% were Grade 1-2, 2.2% were Grade 3, and 0.4% were Grade 4. The median time to onset was 1 hour (range 0.1 to 18 hours) after start of infusion. The incidence of infusion modifications due to IRR was 62% and 1.3% of patients permanently discontinued RYBREVANT® due to IRR.

Premedicate with antihistamines, antipyretics, and glucocorticoids and infuse RYBREVANT® as recommended. Administer RYBREVANT® via a peripheral line on Week 1 and Week 2. Monitor patients for any signs and symptoms of infusion reactions during RYBREVANT® infusion in a setting where cardiopulmonary resuscitation medication and equipment are available. Interrupt infusion if IRR is suspected. Reduce the infusion rate or permanently discontinue RYBREVANT® based on severity.

Interstitial Lung Disease/Pneumonitis

RYBREVANT® can cause interstitial lung disease (ILD)/pneumonitis. Based on the safety population, ILD/pneumonitis occurred in 3.3% of patients treated with RYBREVANT®, with 0.7% of patients experiencing Grade 3 ILD/pneumonitis. Three patients (1%) discontinued RYBREVANT® due to ILD/pneumonitis.

Monitor patients for new or worsening symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold RYBREVANT® in patients with suspected ILD/pneumonitis and permanently discontinue if ILD/pneumonitis is confirmed.

Dermatologic Adverse Reactions

RYBREVANT® can cause rash (including dermatitis acneiform), pruritus and dry skin. Based on the safety population, rash occurred in 74% of patients treated with RYBREVANT®, including Grade 3 rash in 3.3% of patients. The median time to onset of rash was 14 days (range: 1 to 276 days). Rash leading to dose reduction occurred in 5% of patients, and RYBREVANT® was permanently discontinued due to rash in 0.7% of patients.

Toxic epidermal necrolysis occurred in one patient (0.3%) treated with RYBREVANT®.

Instruct patients to limit sun exposure during and for 2 months after treatment with RYBREVANT®. Advise patients to wear protective clothing and use broad-spectrum UVA/UVB sunscreen. Alcohol-free emollient cream is recommended for dry skin.

If skin reactions develop, start topical corticosteroids and topical and/or oral antibiotics. For Grade 3 reactions, add oral steroids and consider dermatologic consultation. Promptly refer patients presenting with severe rash, atypical appearance or distribution, or lack of improvement within 2 weeks to a dermatologist. Withhold, dose reduce or permanently discontinue RYBREVANT® based on severity.

Ocular Toxicity

RYBREVANT® can cause ocular toxicity including keratitis, dry eye symptoms, conjunctival redness, blurred vision, visual impairment, ocular itching, and uveitis. Based on the safety population, keratitis occurred in 0.7% and uveitis occurred in 0.3% of patients treated with RYBREVANT®. All events were Grade 1-2. Promptly refer patients presenting with eye symptoms to an ophthalmologist. Withhold, dose reduce or permanently discontinue RYBREVANT® based on severity.

Embryo-Fetal Toxicity

Based on its mechanism of action and findings from animal models, RYBREVANT® can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during treatment and for 3 months after the final dose of RYBREVANT®.

Adverse Reactions

The most common adverse reactions (≥20%) were rash (84%), IRR (64%), paronychia (50%), musculoskeletal pain (47%), dyspnea (37%), nausea (36%), fatigue (33%), edema (27%), stomatitis (26%), cough (25%), constipation (23%), and vomiting (22%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased lymphocytes (8%), decreased albumin (8%), decreased phosphate (8%), decreased potassium (6%), increased alkaline phosphatase (4.8%), increased glucose (4%), increased gamma-glutamyl transferase (4%), and decreased sodium (4%).

Please read full Prescribing Information for RYBREVANT®.

cp-213274v2

Janssen

Janssen

© Janssen Biotech, Inc. 2021. All rights reserved.

This site is published by Janssen Biotech, Inc., which is solely responsible for its contents. This site is intended for use by healthcare professionals of the United States and Puerto Rico. Janssen Biotech, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and Puerto Rico.

Third party trademarks used herein are trademarks of their respective owners.

Legal Notice | Privacy Policy |  Contact Us | Site Map 

Do not sell my personal information

Last Updated December 2021 cp-206563v1

You are leaving the RYBREVANT® website

You are being directed to a third-party website. Please note that this third-party website is not controlled by Janssen Biotech, Inc., or subject to our Privacy Policy.

Go to link
Cancel

For Healthcare Providers

The information contained at RYBREVANThcp.com is intended for US healthcare providers only. If you are a healthcare provider, click Continue below.

Cancel

registerform-background

Sign up to receive the latest news and information about RYBREVANT® by completing the registration form below.

The information you provide will be used by Janssen Biotech, Inc., our affiliates, and our service providers to send you RYBREVANT® information updates. You may ask to withdraw from receiving these messages by calling 1-800-JANSSEN (1-800-526-7736). Our Privacy Policy further governs the use of the information you provide. By providing the information and selecting the Submit button, you indicate that you have read, understand, and agree to these terms.

*Required field

find-a-repo-background

Talk with a Janssen representative

Please provide your ZIP code and contact information below if you would like us to locate a Janssen Oncology sales representative near you.

The information you provide will be used by Janssen Biotech, Inc., our affiliates, and our service providers to have a Janssen representative contact you. Our Privacy Policy further governs the use of the information you provide. By providing the information and selecting the Submit button, you indicate that you have read, understand, and agree to these terms.

*Required field